Valuation Metrics and Recent Changes
Entero Healthcare Solutions currently trades at a P/E ratio of 43.66, which, while elevated in absolute terms, is considered attractive within its peer group and industry context. This valuation is a marked improvement from previous assessments that rated the stock as fairly valued. The price-to-book value stands at 2.96, reflecting a reasonable premium over the company's net asset value, especially when compared to more expensive peers such as Tata Elxsi and Tata Technologies, which exhibit P/E ratios of 36.78 and 39.99 respectively but are rated as expensive or very expensive.
Enterprise value to EBITDA (EV/EBITDA) for Entero is 24.04, which is competitive relative to peers like Tata Elxsi (29.09) and Tata Technologies (26.81). This metric suggests that the company’s earnings before interest, taxes, depreciation, and amortisation are being valued at a more reasonable multiple, enhancing its attractiveness from a valuation standpoint.
Peer Comparison Highlights
Within the retailing sector, Entero Healthcare Solutions stands out for its valuation grade upgrade to "attractive" by MarketsMOJO, supported by a Mojo Score of 71.0 and a recent upgrade from Hold to Buy on 28 April 2026. This contrasts with several peers classified as very expensive or risky, such as Pine Labs with a P/E of 569.81 and Netweb Technologies at 128.08, both carrying significantly higher valuation multiples that may deter value-conscious investors.
Other companies like KPIT Technologies also share an attractive valuation status but at a lower P/E of 26.5, indicating Entero’s valuation is justified by its growth prospects and operational metrics.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Financial Performance and Returns Analysis
Despite a recent day decline of 3.74%, Entero Healthcare Solutions has delivered a year-to-date return of 16.66%, outperforming the Sensex which has declined by 9.78% over the same period. This outperformance underscores the company’s resilience and growth potential amid broader market volatility.
However, the stock has experienced a negative return over the past year of -9.59%, slightly worse than the Sensex’s -4.15%, indicating some short-term headwinds. Over longer horizons, data is unavailable, but the company’s current valuation upgrade suggests improving fundamentals and investor sentiment.
Profitability and Efficiency Metrics
Entero’s return on capital employed (ROCE) stands at 8.59%, while return on equity (ROE) is 6.26%. These figures, though modest, are consistent with the company’s valuation upgrade and reflect steady operational efficiency. The PEG ratio of 1.34 further supports the notion that the stock is reasonably priced relative to its earnings growth potential.
Other valuation multiples such as EV to capital employed (2.69) and EV to sales (0.91) indicate that the company is not overleveraged and maintains a balanced capital structure, which is favourable for sustaining growth and managing risks.
Market Price and Trading Range
Currently priced at ₹1,196.65, Entero Healthcare Solutions is trading below its 52-week high of ₹1,509.90 but comfortably above its 52-week low of ₹944.00. The recent trading range, with a day’s high of ₹1,242.00 and low of ₹1,190.45, suggests some volatility but also potential for upside as the market digests the valuation upgrade and improved fundamentals.
Valuation Outlook and Investment Implications
The shift from a fair to an attractive valuation grade by MarketsMOJO reflects a positive reassessment of Entero Healthcare Solutions’ price attractiveness. Investors should note that while the P/E ratio remains elevated compared to traditional benchmarks, it is justified by the company’s growth prospects, operational metrics, and relative valuation within its peer group.
Given the small-cap status and the recent upgrade to a Buy rating, Entero Healthcare Solutions presents a compelling opportunity for investors seeking exposure to the retailing sector with a focus on companies demonstrating improving fundamentals and reasonable valuation multiples.
Want to dive deeper on Entero Healthcare Solutions Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Risks and Considerations
While the valuation upgrade is encouraging, investors should remain mindful of the stock’s recent short-term underperformance relative to the Sensex and the inherent volatility associated with small-cap stocks. The retailing sector can be sensitive to economic cycles and consumer sentiment, which may impact Entero’s earnings trajectory.
Moreover, the absence of dividend yield data suggests that the company is reinvesting earnings for growth rather than returning cash to shareholders, which may not suit income-focused investors.
Conclusion
Entero Healthcare Solutions Ltd’s recent valuation shift from fair to attractive, supported by a comprehensive analysis of P/E, P/BV, and other key financial metrics, positions the stock as a noteworthy candidate for investors seeking growth opportunities in the retailing sector. The company’s improved Mojo Grade to Buy and a solid Mojo Score of 71.0 further reinforce this positive outlook.
With a current market price below its 52-week high and a valuation that compares favourably against peers, Entero offers a balanced risk-reward profile. Investors should consider this stock within the context of their portfolio strategy, factoring in sector dynamics and company-specific fundamentals.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
